CDx development
FDA Approves Janssen's Rybrevant, Guardant360 CDx for EGFR Exon 20-Mutated NSCLC
The agency approved amivantamab for non-small cell lung cancer patients harboring EGFR exon 20 mutations, as detected by Guardant Health's blood-based test.
Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.
Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib
Avapritinib is sold by Blueprint Medicines as Ayvakit for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.
Thermo Fisher Scientific, Daiichi Sankyo Partner to Develop Non-Small Cell Lung Cancer CDx
The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.
Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic
Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.
Jun 20, 2018
Feb 28, 2017
Oct 5, 2015